Eagle Pharmaceuticals, Inc. (EGRX) financial statements (2022 and earlier)

Company profile

Business Address 50 TICE BOULEVARD, SUITE 315
WOODCLIFF LAKE, NJ 07677
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments102,971103,155109,77578,791114,65752,82079,083
Cash and cash equivalents97,659103,155109,77578,791114,65752,82079,083
Short-term investments5,312      
Receivables41,14951,11748,00466,48653,82142,19426,267
Inventory, net of allowances, customer advances and progress billings21,9088,0756,5668,3045,1182,73915,042
Inventory21,9088,0756,5668,3045,1182,73915,042
Prepaid expense1,3691914,8525,8899,7131,789726
Other current assets3,1591,6051,445134561355220
Other undisclosed current assets2,0501,9228,8074,2404,8279,213919
Total current assets:172,606166,065179,449163,844188,697109,110122,257
Noncurrent Assets
Property, plant and equipment1,6362,0772,2022,3976,8203,3162,205
Intangible assets, net (including goodwill)50,41452,66055,32657,84663,06573,115 
Goodwill39,74339,74339,74339,74339,74339,743 
Intangible assets, net (excluding goodwill)10,67112,91715,58318,10323,32233,372 
Regulated entity, other noncurrent assets   6001,000  
Deferred income tax assets18,79815,18013,669
Other noncurrent assets10,27817,2083,908694124136143
Other undisclosed noncurrent assets   13,22210,35428,643 
Total noncurrent assets:81,12687,12575,10574,75981,363105,2102,348
TOTAL ASSETS:253,732253,190254,554238,603270,060214,320124,605
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48,76930,08533,82333,43627,37239,95328,262
Accounts payable16,4316,2685,4629,91711,98114,7163,857
Accrued liabilities32,33823,81728,36123,51915,39125,23724,405
Debt25,6078,0005,0006,2504,875  
Business combination, contingent consideration, liability    15,0551,012 
Deferred revenue and credits  6,000
Total current liabilities:74,37638,08538,82339,68647,30240,96534,262
Noncurrent Liabilities
Long-term debt and lease obligation 25,13533,55738,15542,905  
Long-term debt, excluding current maturities 25,13533,55738,15542,905  
Liabilities, other than long-term debt2,9033,9593,000 70922,129 
Other liabilities2,9033,9593,000    
Business combination, contingent consideration, liability    70922,129 
Total noncurrent liabilities:2,90329,09436,55738,15543,61422,129 
Total liabilities:77,27967,17975,38077,84190,91663,09434,262
Stockholders' equity
Stockholders' equity attributable to parent176,453186,011179,174160,762179,144151,22690,343
Common stock17171717161615
Treasury stock, value(225,111)(203,898)(171,861)(153,900)(80,795)(37,003) 
Additional paid in capital325,779305,403278,518256,458233,639213,872197,440
Accumulated other comprehensive loss(94)      
Retained earnings (accumulated deficit)75,86284,48972,50058,18726,284(25,659)(107,112)
Total stockholders' equity:176,453186,011179,174160,762179,144151,22690,343
TOTAL LIABILITIES AND EQUITY:253,732253,190254,554238,603270,060214,320124,605

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues171,546187,802195,892213,312236,707189,48266,227
Revenue, net236,707189,48266,227
Cost of revenue(31,528)(33,647)(47,891)(42,374)(33,714)(34,320)(15,647)
Cost of goods and services sold(31,528)(33,647)(47,891)(42,374)(33,714)(34,320) 
Other undisclosed gross profit  (13,006)    
Gross profit:140,018154,155134,995170,938202,993155,16250,580
Operating expenses(137,249)(121,201)(126,186)(176,696)(162,717)(136,131)(63,667)
Other undisclosed operating income  13,00642,37433,71434,32015,647
Operating income:2,76932,95421,81536,61673,99053,3512,560
Nonoperating income (expense)(7,317)(10,277)183(2,578)(1,045)7614
Investment income, nonoperating5605622,169158918425
Other nonoperating income (expense)(6,242)(8,262)700    
Interest and debt expense(1,635)(2,577)(2,686)(2,736)(300)(8)(11)
Income (loss) from continuing operations before equity method investments, income taxes:(6,183)20,10019,31231,30272,64553,4192,563
Other undisclosed income from continuing operations before income taxes1,6352,5772,6862,736300811
Income (loss) from continuing operations before income taxes:(4,548)22,67721,99834,03872,94553,4272,574
Income tax expense (benefit)(4,079)(10,688)(7,685)(2,135)(21,002)28,026(3)
Net income (loss) available to common stockholders, diluted:(8,627)11,98914,31331,90351,94381,4532,571

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(8,627)11,98914,31331,90351,94381,4532,571
Comprehensive income (loss):(8,627)11,98914,31331,90351,94381,4532,571
Other undisclosed comprehensive loss, net of tax, attributable to parent(94)      
Comprehensive income (loss), net of tax, attributable to parent:(8,721)11,98914,31331,90351,94381,4532,571

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: